Drug profile · INN
nelfinavir mesylate
VIRACEPT
nelfinavir mesylate (VIRACEPT) is a human immunodeficiency virus type 1 protease inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — nelfinavir mesylate
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
nelfinavir mesylate (VIRACEPT) is a human immunodeficiency virus type 1 protease inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Human immunodeficiency virus type 1 protease inhibitor
Primary target: Human immunodeficiency virus type 1 protease
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is nelfinavir mesylate?
nelfinavir mesylate (VIRACEPT) is a human immunodeficiency virus type 1 protease inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for nelfinavir mesylate?
VIRACEPT is a marketed brand name for nelfinavir mesylate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of nelfinavir mesylate?
nelfinavir mesylate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.